Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan

BMC Health Services Research

Daniel Bin Ng¹  Manabu Akazawa²  Kenichi Sakakura³  Ayano Okabe⁴  Hideki Maeda⁴ 

[1] Department of Health Economy Outcome Research, Astellas Pharma Global Development, Singapore, Singapore;Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA;Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, Japan;Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, Japan;Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi-honcho, Chuo-ku, 103-8426, Tokyo, Japan;Department of Regulatory Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, 204-8588, Tokyo, Japan;

关键词: Anticancer drug;    Oncology;    Drug price revision;    Additional indications;    Japan;    National Health Insurance drug price;   

DOI  :  10.1186/s12913-021-07360-w

来源: Springer

【 摘 要 】

BackgroundThe relationships between developmental strategies for additional indications and drug price revisions have not been thoroughly studied. Here, we investigated the price revisions for anticancer drugs approved in Japan.MethodsThe study was based on published information on anticancer drugs approved between January 2009 and March 2020 in Japan. We investigated the relationships between the pharmacological and regulatory characteristics of anticancer drugs and occurrence/non-occurrence of the Japanese National Health Insurance (NHI) price revisions.ResultsEighty-one new anticancer drugs were given NHI price listings during the survey. On April 1, 2020, the prices of 23 anticancer drugs had been revised from the initial pricing, the prices were reduced for 21 drugs (91.3%). Several parameters showed the relationships between drug characteristics and NHI price revisions. The achievement of additional indications and compound type were identified as explanatory factors for these relationships. Additional indication profiles were defined to assess the relationships between the methods for additional indication achievement and price revisions. When the type of additional indication was “Expansion”, the percentage of drugs received NHI price revisions was the highest (P<0.001).ConclusionsNHI price revision was significantly related to the achievement of additional indications and compound type. The strategy for additional indications was found to affect the occurrence/non-occurrence of NHI price revisions.

【 授权许可】

CC BY